anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: End-stage renal disease is a health concern around the world. Kidney transplant substantially improves survival compared with dialysis. Although kidney transplant is the better choice for treatment of end-stage renal disease, most patients refuse this option. In this study, we aimed to find the most common reasons why patients did not undergo a kidney transplant.
MATERIALS AND METHODS: We conducted a cross-sectional study involving 263 patients on chronic hemodialysis in hemodialysis centers in Shiraz, Iran, in 2024. We collected data via structured interviews, which had questions on demographics, disease characteristics, dialysis details, and reasons for transplant refusal. P < .05 was considered significant.
RESULTS: In our study cohort, mean age was 60.2 ± 16.8 years and 57.8% were male patients. The most prevalent reason for refusing kidney transplant was patient-centric barriers for kidney transplant (47.7%); difficulties with the transplant process included financial concern (33.7%), unacceptability of outcomes (30.2%), and worries about the unpredictability of transplant outcome (24.1%). The mean age of patients on the kidney transplant waiting list was 51.7 ± 16.4 years, and mean age of those who declined a kidney transplant was 60.2 ± 16.8 years (P < .001). Among patients on the waiting list, 68.7% were married compared with 81.7% of patients who declined a kidney transplant (P = .011).
CONCLUSIONS: Addressing financial concerns by possibly improving insurance coverage, enhancing patient education on transplant benefits and risks, and providing psychological support can potentially increase acceptance rates. Tailored interventions focusing on individual patient concerns and improving communication between health care providers and patients are essential.
OBJECTIVE: This study explores the mechanism of action of Danhongqing formula (DHQ), a compound-based Chinese medicine formula, in the treatment of cholestatic liver fibrosis.
METHODS: In vivo experiments were conducted using 8-week-old multidrug resistance protein 2 knockout (Mdr2-/-) mice as an animal model of cholestatic liver fibrosis. DHQ was administered orally for 8 weeks, and its impact on cholestatic liver fibrosis was evaluated by assessing liver function, liver histopathology, and the expression of liver fibrosis-related proteins. Real-time polymerase chain reaction, Western blot, immunohistochemistry and other methods were used to observe the effects of DHQ on long non-coding RNA H19 (H19) and signal transducer and activator of transcription 3 (STAT3) phosphorylation in the liver tissue of Mdr2-/- mice. In addition, cholangiocytes and hepatic stellate cells (HSCs) were cultured in vitro to measure the effects of bile acids on cholangiocyte injury and H19 expression. Cholangiocytes overexpressing H19 were constructed, and a conditioned medium containing H19 was collected to measure its effects on STAT3 protein expression and cell activation. The intervention effect of DHQ on these processes was also investigated. HSCs overexpressing H19 were constructed to measure the impact of H19 on cell activation and assess the intervention effect of DHQ.
RESULTS: DHQ alleviated liver injury, ductular reaction, and fibrosis in Mdr2-/- mice, and inhibited H19 expression, STAT3 expression and STAT3 phosphorylation. This formula also reduced hydrophobic bile acid-induced cholangiocyte injury and the upregulation of H19, inhibited the activation of HSCs induced by cholangiocyte-derived conditioned medium, and decreased the expression of activation markers in HSCs. The overexpression of H19 in a human HSC line confirmed that H19 promoted STAT3 phosphorylation and HSC activation, and DHQ was able to successfully inhibit these effects.
CONCLUSION: DHQ effectively alleviated spontaneous cholestatic liver fibrosis in Mdr2-/- mice by inhibiting H19 upregulation in cholangiocytes and preventing the inhibition of STAT3 phosphorylation in HSC, thereby suppressing cell activation. Please cite this article as: Li M, Zhou Y, Zhu H, Xu LM, Ping J. Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation. J Integr Med. 2024; 22(2): 188-198.
The invention relates to medicine for treating acute gastroenteritis and a preparation method thereof. The medicine is composed of 17 species of traditional Chinese medicine including kudzu vine root, agastache rugosus, rhizoma atractylodis, fructus amomi and the like. The dosage form of the medicine includes oral liquid, capsule, tablet and the like. The acute gastroenteritis is an acute gastrointestinal tract disease caused by various reasons including bacteria, virus, chemical drugs, residual pesticide, impure deteriorating toxic food, intemperance, engorgement and the like. Symptoms appear within 24 hours in most time. Main clinical features includes midsection discomfort, stomachache, bellyache, turgor, nausea, vomiting, diarrhea, watery stool and even paroxysmal gastrointestinal colic. Severely, patients have nausea, vomit, have diarrhea continuously and quickly have the critical symptoms of dehydration, acidosis, shock, exhaustion, collapse and the like. The treating principle of the acute gastroenteritis includes coursing the exterior, scattering cold, clearing heat and dampness, warming the middle, strengthening the spleen and the stomach, regulating vital energy and facilitating urination. The prescription of the medicine is formed by summarizing clinical practices in long time, no similar pure traditional Chinese medicine exists in the existing documents by search, and the medicine is a practical medicament for first aid for clinical use, household use and travel use.
PURPOSE:To obtain the titled slightly yellow and transparent substance having effects on the remedy of skin disease and beautifying effect free from stimulation, by blending a solution of coicis semen pulveratum with iodine, to give a colored solution, treating the solution with enzyme so that it is faded. CONSTITUTION:Coicis semen pulveratum is gelatinized and made into a paste to give a solution, to which iodine is added to prepare a colored solution. The solution is treated with enzyme (e.g., amylase, protease) at >= about 40 deg.C and faded. Insoluble substances are filtered off from the faded solution to give a slightly yellow and transparent solution. Coicis semen pulveratum is obtained by removing pericarp and seed coat from the fruit of a chicken breast, a gramineous plant, and has been used as a medical decoction. It is not used easily for external use, and its application has been limited because of the dark brown and stimulation of iodine of its own. Both the compounds are blended and made into the solution by this method, so the above-mentioned defects are solved while providing improved medicinal effects and beautifying effects.
Patients who agree to participate in the study will be included in the experimental group and control group as a result of statistical analysis and the number of patients will be determined. Then, the patients will be assigned to the groups with the randomisation method of;simple and stratified sampling;. The experimental and control groups within the scope of the research will be determined by simple randomisation method (coin toss). In the first interview, the individuals in the training group will be administered the Individual Information Form; and the;Attitude Scale of Hemodialysis Patients towards Diet Therapy as a pre-test by the researcher using the face-to-face interview method. Then, 24-Hour Food Consumption Record will be given and all food/liquids eaten and drunk for 24 hours retrospectively will be asked to be written on this form. At this stage, the researchers will help the participants to fill in the food consumption record if needed. This process will take approximately 20 minutes and the food consumption record will be collected again. Then, the individuals in the training group will be informed about nutrition education and the first nutrition education will be started. The training will last for 4 weeks, twice a week, and the length of the training will be forty minutes. After the last of the trainings, which will last 8 times in total, the Attitude Scale of Hemodialysis Patients towards Diet Therapy will be applied as a post-test using the face-to-face interview method. In the same way, 24-Hour Food Consumption Record will be given and all food/liquids eaten and drunk for 24 hours retrospectively will be asked to be written on this form. In the control group, pretest data forms (Individual Information Form and Attitude Scale towards Diet Therapy of Haemodialysis Patients) and three-day 24-Hour Food Consumption Record will be filled out, and the Attitude Scale and three-day 24-Hour Food Consumption Record will be filled out one month later as the posttest.
Group II: (Silymarin group ; n=32) which will receive FOLFIRI regimen (5-flourouracil, leucovorin, irinotecan) or XELIRI (Capecitabine and irinotecan) with or without target therapy (Bevacizumab). plus silymarin 140 mg once daily.
Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
Inflammatory bowel disease (IBD) is a group of intestinal inflammatory diseases characterized by chronic, recurrent, remitting, or progressive inflammation, which causes the disturbance of the homeostasis between immune cells, such as macrophages, epithelial cells, and microorganisms. Intestinal macrophages (IMs) are the largest population of macrophages in the body, and the abnormal function of IMs is an important cause of IBD. Most IMs come from the replenishment of blood monocytes, while a small part come from embryos and can self-renew. Stimulated by the intestinal inflammatory microenvironment, monocyte-derived IMs can interact with intestinal epithelial cells, intestinal fibroblasts, and intestinal flora, resulting in the increased differentiation of proinflammatory phenotypes and the decreased differentiation of anti-inflammatory phenotypes, releasing a large number of proinflammatory factors and aggravating intestinal inflammation. Based on this mechanism, inhibiting the secretion of IMs' proinflammatory factors and enhancing the differentiation of anti-inflammatory phenotypes can help alleviate intestinal inflammation and promote tissue repair. At present, the clinical medication of IBD mainly includes 5-aminosalicylic acids (5-ASAs), glucocorticoid, immunosuppressants, and TNF-α inhibitors. The general principle of treatment is to control acute attacks, alleviate the condition, reduce recurrence, and prevent complications. Most classical IBD therapies affecting IMs function in a variety of ways, such as inhibiting the inflammatory signaling pathways and inducing IM2-type macrophage differentiation. This review explores the current understanding of the involvement of IMs in the pathogenesis of IBD and their prospects as therapeutic targets.
Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
Multiple myeloma (MM) is primarily a disease of older patients. Until recently, geriatric aspects in the context of MM have been poorly investigated. Treatment outcomes for geriatric patients with MM are often compromised by comorbidities and an enhanced susceptibility to adverse events from therapy. Assessment of patient frailty has become more frequent and will be useful in the context of significant and continuous advances in therapy. The recent emergence of immunotherapy with CD38 monoclonal antibodies and upcoming immunooncology drugs, such as bispecific antibodies, will lead to additional therapeutic progress. The applicability of these new molecules to older and frail patients is a key clinical question. Here, we present 2 patient cases derived from clinical practice. We review current frailty scores and standards of care for older, newly diagnosed patients with MM, including frail subgroups, and discuss ways to tailor treatment, as well as treatment perspectives in this population.
MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
Myocarditis or inflammatory cardiomyopathy refers to inflammation of the myocardium. Sarcoidosis is a multisystem granulomatous disorder of unknown etiology, which can result in myocardial inflammation. Approximately 5% of patients with sarcoidosis have clinically apparent cardiac involvement, yet autopsy series indicate that cardiac involvement is present in up to 25% of cases. This discrepancy suggests that cardiac sarcoidosis may be under-diagnosed in clinical practice. Recent studies have demonstrated high diagnostic accuracy of both cardiac MRI and 18F-labelled fluoro-2-deoxyglucose (FDG) PET for detection of cardiac involvement. However, cardiac MRI may fail to identify areas of active inflammation even with fluid sensitive T2-weighted sequences.

Fasting 18F-FDG positron emission tomography (PET) has been shown to identify early cardiac sarcoidosis with relatively high sensitivity. To date, simultaneous PET/MRI evaluation of cardiac inflammation and sarcoidosis has only been described in limited case reports. The objective of the proposed research is to evaluate the utility of simultaneous PET/MRI imaging in patients with cardiac sarcoidosis and other inflammatory cardiomyopathies.
An exercise program organized by the researchers (same exercise program as the vibration group) will be applied to the pre-frail participants in the control group on a flat surface. The exercises will be applied 5 days a week for 6 weeks.
BACKGROUND: Hearing impairment (HI) has become a major public health issue in China. Currently, due to the limitations of primary health care, the gold standard for HI diagnosis (pure-tone hearing test) is not suitable for large-scale use in community settings. Therefore, the purpose of this study was to develop a cost-effective HI screening model for the general population using machine learning (ML) methods and data gathered from community-based scenarios, aiming to help improve the hearing-related health outcomes of community residents.
METHODS: This study recruited 3371 community residents from 7 health centres in Zhejiang, China. Sixty-eight indicators derived from questionnaire surveys and routine haematological tests were delivered and used for modelling. Seven commonly used ML models (the naive Bayes (NB), K-nearest neighbours (KNN), support vector machine (SVM), random forest (RF), eXtreme Gradient Boosting (XGBoost), boosting, and least absolute shrinkage and selection operator (LASSO regression)) were adopted and compared to develop the final high-frequency hearing impairment (HFHI) screening model for community residents. The model was constructed with a nomogram to obtain the risk score of the probability of individuals suffering from HFHI. According to the risk score, the population was divided into three risk stratifications (low, medium and high) and the risk factor characteristics of each dimension under different risk stratifications were identified.
RESULTS: Among all the algorithms used, the LASSO-based model achieved the best performance on the validation set by attaining an area under the curve (AUC) of 0.868 (95% confidence interval (CI): 0.847-0.889) and reaching precision, specificity and F-score values all greater than 80%. Five demographic indicators, 7 disease-related features, 5 behavioural factors, 2 environmental exposures, 2 hearing cognitive factors, and 13 blood test indicators were identified in the final screening model. A total of 91.42% (1235/1129) of the subjects in the high-risk group were confirmed to have HI by audiometry, which was 3.99 times greater than that in the low-risk group (22.91%, 301/1314). The high-risk population was mainly characterized as older, low-income and low-educated males, especially those with multiple chronic conditions, noise exposure, poor lifestyle, abnormal blood indices (e.g., red cell distribution width (RDW) and platelet distribution width (PDW)) and liver function indicators (e.g., triglyceride (TG), indirect bilirubin (IBIL), aspartate aminotransferase (AST) and low-density lipoprotein (LDL)). An HFHI nomogram was further generated to improve the operability of the screening model for community applications.
CONCLUSIONS: The HFHI risk screening model developed based on ML algorithms can more accurately identify residents with HFHI by categorizing them into the high-risk groups, which can further help to identify modifiable and immutable risk factors for residents at high risk of HI and promote their personalized HI prevention or intervention.
FIELD: medicine. SUBSTANCE: remedy based on water-soluble hydrolysis products represented by certain organic compounds has thermoresistant low molecular weight morphoplasm and cell glycocalyx components modified in embryogenesis and/or proliferation and/or pathologic processes preceding or accompanying the tissue restoration and/or repair present among hydrolysis products. Method for producing the biologically active remedy involves comminuting washed animal tissue raw materials, hydrolyzing the obtained ingredients, their filtering and separating supernatant as the end product. Animal tissue with modified morphoplasm and cell glycocalyx components is used as raw materials homogenized and deprived of undamaged animal tissue elements with supernatant, containing the ingredients with modified morphoplasm and cell glycocalyx components, having been separated before being exposed to hydrolysis. The preparation for normalizing functional state of human or animal organism has biologically active remedy produced on the base of animal tissue elements hydrolysis products and filler thermoresistant low molecular weight morphoplasm and cell glycocalyx components in the amount of 0.001- 85.0% by mass with the rest completed by the filler. The method for normalizing physiological state of human or animal organism involves administering the preparation based on the animal tissue elements hydrolysis products being a composition of the biologically active remedy containing the modified morphoplasm and cell glycocalyx components among hydrolysis products and filler in the amount of 0.001-85.0 and 15.0-99.999% by mass, respectively. EFFECT: enhanced immunomodulating effectiveness. 31 cl, 12 tbl
A technique for generating a data set that geometrically defines a bone cut configuration for transverse maxillary distraction is described. A computer- implemented method aspect of that technique comprises creating a numeric model of a maxilla based on patient-specific data of the maxilla. The numeric model is representative of mechanic properties of the maxilla. Based on the numeric model thus generated, one or more cut configurations for one or more bone cuts on at least one of a left hand side and a right hand side of the maxilla are determined. Each cut configuration has been determined to compensate for asymmetric mechanic properties of the maxilla. In a further step, a data set indicative of the one or more cut configurations thus determined is generated. The data set may be used to create a surgical template or jig, for a computer-assisted surgery or in connection with a surgical navigation system.
This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
Infectious diseases are a major threat to global health and cause millions of deaths every year, particularly in developing countries. The emergence of multidrug resistance challenges current antimicrobial treatments, inducing uncertainty in therapeutic protocols. New compounds are therefore necessary. A drug repurposing approach could play a critical role in developing new treatments used either alone or in combination with standard therapy regimens. Herein, we focused on cysteamine, an aminothiol endogenously synthesized by human cells during the degradation of coenzyme-A, which is a drug approved for the treatment of nephropathic cystinosis. Cysteamine influences many biological processes due to the presence of the highly reactive thiol group. This review provides an overview of cysteamine-mediated effects on different viruses, bacteria and parasites, with a particular focus on infections caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Mycobacterium tuberculosis, non-tuberculous mycobacteria (NTM), and Pseudomonas aeruginosa. Evidences for a potential use of cysteamine as a direct antimicrobial agent and/or a host-directed therapy, either alone or in combination with other antimicrobial drugs, are described.
Heat is a cardinal feature of inflammation, yet its impacts on immune cells remain uncertain. We show that moderate-grade fever temperatures (39°C) increased murine CD4 T cell metabolism, proliferation, and inflammatory effector activity while decreasing regulatory T cell suppressive capacity. However, heat-exposed T helper 1 (TH1) cells selectively developed mitochondrial stress and DNA damage that activated Trp53 and stimulator of interferon genes pathways. Although many TH1 cells subjected to such temperatures died, surviving TH1 cells exhibited increased mitochondrial mass and enhanced activity. Electron transport chain complex 1 (ETC1) was rapidly impaired under fever-range temperatures, a phenomenon that was specifically detrimental to TH1 cells. TH1 cells with elevated DNA damage and ETC1 signatures were also detected in human chronic inflammation. Thus, fever-relevant temperatures disrupt ETC1 to selectively drive apoptosis or adaptation of TH1 cells to maintain genomic integrity and enhance effector functions.